The role of the c-Met pathway in lung cancer and the potential for targeted therapy. - Test2 - elhamkhani - TriplyDB

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

http://www.wikidata.org/entity/Q35146937

about

The Evolution of Therapies in Non-Small Cell Lung Cancer LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models EGFR-TKI resistance in NSCLC patients: mechanisms and strategies A novel classification of lung cancer into molecular subtypes A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.Molecular pathways and therapeutic targets in lung cancer Prognostic factors in resected lung carcinomas.Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro.Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues.A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Role of MetMAb (OA-5D5) in c-MET active lung malignancies.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Role of c-mesenchymal-epithelial transition pathway in gastric cancer.Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Oncogenic driver mutations in lung cancer.Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions.Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients.

P2860

Q26786932-097727CA-6625-40D5-9743-3E4F063E4D5A Q27675641-D84C1F72-5E5B-48A2-AD4C-50DD4D672493 Q28394310-25686CE7-05FB-4AA1-B248-38B830C8DA74 Q28731874-89173ADB-1B6F-4CC5-A514-E66D3F650C56 Q33162379-727041E1-ABF6-4BE5-B7B1-532EDBE67736 Q33676726-8E2155AC-6A2A-4485-8BB0-3ADA1E705B53 Q33688872-F6A1BB10-7573-49EA-A632-D762D7231D8B Q33697964-6887EBC1-27DE-4560-B17B-06350F9B41FC Q33823276-FAD8B6F4-51E8-4D4B-AECB-1E5BB23F14C5 Q34467527-14B5F189-ED2C-4D69-9047-2582684500DD Q34635475-E1D148D7-C730-4DEB-AE8B-6A0E447F817F Q34964958-41AB6A28-B58B-45E1-ABB0-5E03CADA236C Q35078950-2E24075D-676D-431A-867F-88AA5FEBACAB Q35952832-E8A74520-ABB3-4703-BDF0-84BE35CAA2A7 Q35976337-1B50C895-F035-42D5-81F3-2D2955E69779 Q36189614-6EFE9D6F-7E5E-4729-B777-9CE16132BEFA Q37222790-C6ADE652-87FA-4A50-B08E-54403FE600B5 Q37628915-E293F474-AF48-47A7-B860-D55AB3949612 Q37663252-4F074CC8-F005-4FF3-8516-3A16A1E0C057 Q37739477-3396B137-576F-47A9-BF9D-0CD23FFA523C Q37952015-00437D8D-CCB4-48B5-A568-BF5749F073D4 Q38390200-503E1956-766A-4DAA-A68F-C9A4CD41C6C8 Q38424220-73F25B5B-955A-46CF-A55D-3E9636A4EE5A Q38711090-732DD68F-5226-4BB7-8115-2ECC2C56EDFF Q38735120-BF230D9A-66F2-48E2-AEFA-CDEA9DEF892E Q38799845-B3EB8F5E-48AF-420F-A771-C51F6BED07D0 Q38846405-F5F55A01-AD62-4827-9D6D-F6CE439F6678 Q39048792-2CAFE5B8-7B28-4260-B8C9-EEC33CECF25A Q39127472-4193DB91-1495-4E1A-8D25-6AE7AD88B6A5 Q39369140-C3FF29A6-D957-4FF4-B6FE-33DD3465A3B4 Q42337044-16709999-5C50-4ED6-8F21-E2C0FB436BA4 Q42378535-DD782EC4-3D19-44DD-B6A3-746243746953 Q47897098-4E23A2B7-6AE6-4DB5-8344-D924ED37111E Q50129416-7AB18F32-CF99-4035-9ABA-611AF9B30F67 Q55070113-BA219948-9656-4072-B4A0-1B9F4D922F39

P2860

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

http://www.wikidata.org/entity/Q35146937

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

@ast

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

@en

type

label

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

@ast

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

@en

prefLabel

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

@ast

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

@en

P1433

Q35146937-B6BF3BA1-ECC5-4268-A86F-CEFEA71297AF

P1476

Q35146937-8575FC81-4F1B-4198-AD42-29A363799B97

P2093

Q35146937-2C239B04-8E0F-4CF9-8C6B-C3C4F5ACDFBC

Q35146937-5404391E-827F-4ADC-B24B-8C91B52EA567

Q35146937-598A1282-F4AC-48E1-85E3-7CF73D6EFDB8

Q35146937-AD7D2621-F96E-4389-819D-7A0C339F5D3A

P2860

Q35146937-0804CE75-AD99-4DE2-BB82-E148015B569D

Q35146937-090648C6-A4D0-4A38-BBB9-7DBAFDD1DC1C

Q35146937-0BBB314C-CC1E-4247-B17B-F3445F7077D3

Q35146937-0CAA7793-3B70-4ED8-AF30-5CA5E3360A6A

Q35146937-18B81345-4EF6-43A6-A079-10C006AD202A

Q35146937-18CBA0A6-A764-471A-9BC0-38BB0F9F945A

Q35146937-1BD85E03-2A32-4E24-BF73-369F7F00C730

Q35146937-1C533DF9-9CB3-4444-A68A-713A68A30D6F

Q35146937-1F176408-8C07-4C0C-891C-0F235BC023D0

Q35146937-218C339A-0A51-44B6-B420-C15423795D97

P304

Q35146937-4F16C4CF-3741-4889-A978-EB1E8D8E2365

P31

Q35146937-F42322B7-A4D7-458D-B660-104DCB106422

P356

Q35146937-69668815-E7DB-4A6F-8C90-3FCEF56B8C35

P433

Q35146937-FC4D70EB-AA07-4E9B-8722-8A3FF05D1A22

P478

Q35146937-1E15E84B-1C16-4CD3-9668-547103A0048E

P50

Q35146937-5E2447D1-D98F-4E7C-A21C-90C000C9C652

P577

Q35146937-B6AE02AA-D031-485F-B14D-92216E48D86C

P5875

Q35146937-D5FAE534-EF10-4688-B8EE-8AFD8120F8E2

P698

Q35146937-F54EA9AD-1084-40F3-9C25-2CCD47D7AB64

P932

Q35146937-8385E289-FC60-4F84-AC0D-98DABE19E84E

P356

1758834011408636

P1433

Therapeutic advances in medical oncology

P1476

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

@en

P2093

Mamatha M Reddy

http://www.w3.org/2001/XMLSchema#string

Martin Sattler

http://www.w3.org/2001/XMLSchema#string

Rifat Hasina

http://www.w3.org/2001/XMLSchema#string

Tara Gangadhar

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Cancer statistics, 2010

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development

P304

171-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834011408636

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51636184

http://www.w3.org/2001/XMLSchema#string

P698

21904579

http://www.w3.org/2001/XMLSchema#string

P932

3150066

http://www.w3.org/2001/XMLSchema#string